Quarterly ResultApr 30, 2026, 06:17 AM
VKTX Q1 Net Loss $(158.3M); R&D Expenses +262.7% to $150.2M
AI Summary
Viking Therapeutics reported a net loss of $(158.3) million for Q1 2026, a significant increase from $(45.6) million in Q1 2025. This was primarily driven by a 262.7% surge in research and development expenses to $150.2 million. The company's cash and cash equivalents decreased to $118.1 million, though it raised $11.6 million through an ATM offering. The company also moved into new corporate headquarters in April 2026.
Key Highlights
- Net loss widened to $(158.3) million in Q1 2026 from $(45.6) million in Q1 2025.
- Research and development expenses surged 262.7% to $150.2 million in Q1 2026.
- Basic and diluted net loss per share was $(1.37) for Q1 2026.
- Cash and cash equivalents totaled $118.1 million as of March 31, 2026.
- Short-term investments were $484.8 million as of March 31, 2026.
- Net cash used in operating activities was $(114.0) million in Q1 2026.
- Raised $11.6 million from an ATM offering during Q1 2026.
- Moved into new corporate headquarters in San Diego in April 2026.